18F-FDGSPECT/CT检查在原发癌灶定位诊断中的意义  

The Value of 18F-FDG SPECT/CT Examination in Detecting Primary Tumor for Patients with Carcinoma of Unknown Primary

作　　者：贾晓娟[1] 韩军[2] 许泽清[1] 唐彩华[1] 李慧[1] 

机构地区：[1]中山大学附属第五医院核医学科,广东珠海519000 [2]中山大学附属第五医院化疗科,广东珠海519000

出　　处：《中外医疗》2013年第22期24-24,27,共2页China & Foreign Medical Treatment

摘　　要：目的探讨18F-FDGSPECT/CT检查在原发癌灶定位和鉴别诊断中的价值。方法对107例临床常规检查不能定位的病例进行18F-FDGSPECT/CT显像,进行病理诊断跟踪和12个月临床资料随访。结果该组107例18F-FDGSPECT/CT检查定位原发肿瘤共计94例,定位准确性86.2%;6例未见核素浓聚,假阴性率5.5%。7例18F-FDGSPECT/CT检查和临床随访未能确定原发灶,临床诊断为原发灶不明转移癌,占6.4%。结论 18F-FDGSPECT/CT作为一种对细胞代谢和影像显示的检查,在原发灶定位和鉴别诊断中具有较高的价值。Objective To investigate the value of 18F-FDG SPECT/CT whole body imaging in detecting primary tumors and differential diagnosis. Methods 107 patients with unknown primary origin were referred for 18F-FDG SPECT/CT whole body imaging. Histpathologic and 12-months formal clinical fellow-up findings were used to assess the value of 18F-FDG SPECT/CT. Results 18F-FDG SPECT/CT was able to detect the primary tumor in 94 of 107 patients with positioning accuracy was 86.2%; 18F-FDG SPECT/CT results were proved no nuclide concentration in 6 patients with false negative rate was 5.5%; 18F-FDG SPECT/CT and 12-months fellow-up findings could not detect the primary tumor of 7 patients, who were diagnosed clinically as cancer of un- known primary site with the failure to diagnose rate was 6.4%. Conclusion As a kind of examination of cell metabolism and image display, 18F-FDG SPECT/CT whole body imaging have a certain clinical value in detecting primary tumors and differential diagno- sis for patients with carcinoma of unknown primary.

关 键 词：18F-FDGSPECT CT 原发灶不明肿瘤 定位诊断 

分 类 号：R4[医药卫生—临床医学]